BiotechTubeBiotechTube
Home/Pipeline/NPM-133

NPM-133

Type 2 Diabetes

PreclinicalUnder development

Key Facts

Indication
Type 2 Diabetes
Phase
Preclinical
Status
Under development
Company
Vivani Medical

About Vivani Medical

Vivani Medical aims to revolutionize chronic disease treatment by eliminating adherence challenges through its miniaturized, subdermal drug implants. The company's NanoPortal™ technology has been validated in a successful Phase 1 trial (LIBERATE-1) and is now being applied to a pipeline focused on GLP-1 agonists for obesity and type 2 diabetes. With a veteran leadership team and a public listing on NASDAQ, Vivani is positioned to advance its long-acting implant solutions through clinical development.

View full company profile

Therapeutic Areas

ObesityType 2 DiabetesCardiometabolic DisordersNeuromodulation

Other Type 2 Diabetes Drugs

DrugCompanyPhase
Tirzepatide (Mounjaro)Eli LillyApproved
OrforglipronEli LillyPhase 3
Trulicity (dulaglutide)Eli LillyApproved
ForxigaAstraZenecaApproved
siRNA GalXC-GYS2Novo NordiskPhase 1
Amylin/semaglutide combinationNovo NordiskPhase 3
LipaglynZydus LifesciencesApproved
LBS-009Belite BioPreclinical
Jentadueto (Linagliptin/Metformin)YuhanApproved
Nesina (Alogliptin)YuhanApproved
Metformin & CombinationsIpca LaboratoriesCommercial
GSBR-1290Structure TherapeuticsPhase 2